Viatris dans l'actualité
Fourniture d'un vaste portefeuille de médicaments
Tamtam a trouvé 18 articles récents sur Viatris.
- Viatris to Report Third-Quarter 2026 Financial Results on November 5, 2026
- Harrow Closes Acquisition of Tyrvaya, a Dry Eye Disease Treatment From Viatris Inc.
- A third-quarter results call is set for 8:30 a.m. ET on Nov. 5, with Viatris executives hosting.
- Viatris’s pipeline strategy: Moving beyond generics to find new growth
- Should Value Investors Buy Viatris (VTRS) Stock?
- Harrow Closes Acquisition of Tyrvaya from Viatris
- Viatris to Report Third-Quarter 2026 Financial Results on November 5, 2026
- UBS Adjusts Price Target on Viatris to $26 From $23, Keeps Buy Rating
- Viatris to report Q3 2026 earnings on Nov 5 wit...
- UBS raises Viatris stock price target on cenerimod outlook
- Net income before discontinued operations of Viatris, Inc. – HAN:VIA
- Viatris Inc. stock falls Wednesday, underperforms market
- Return on invested capital % of Viatris, Inc. – HAN:VIA
- Viatris Recognized by Forbes as One of the World's Best Employers for the Sixth Consecutive Year
- Viatris named to Forbes' World's Best Employers list for sixth year, highlighting strong workplace culture.
- Will Japan WAKIX Approval Change Viatris (VTRS) Stock Narrative
- Is Viatris (VTRS) Cheap On Its Japan WAKIX Approval?
- Viatris sues Novo Nordisk over generic Wegovy patent dispute
Articles collectés par Tamtam et retenus lorsqu'ils portent sur l'entreprise, des plus récents aux plus anciens. Chacun renvoie à sa source.
Vous vendez à des entreprises comme Viatris ?
Tamtam trouve les entreprises qui correspondent à votre client idéal, analyse chaque compte et vous dit qui contacter, et quand.
Trouver des entreprises similaires